The U.S. Food and Drug Administration (FDA) approved Poherdy (pertuzumab-dpzb) as the first interchangeable biosimilar to ...

Conclusion: Patients with normal serum HER-2/neu receiving letrozole demonstrated a significantly greater ORR and CB and longer TTP and TTF than patients receiving tamoxifen. Although in patients with ...

CONCLUSION: The majority of patients with HER-2/neu–overexpressing cancers can develop immunity to both HER-2/neu peptides and protein. In addition, the generation of protein-specific immunity, after ...

Breast Tumor Section showing nonamplified HER-2/neu (<4 signals/nucleus). Cells are stained with DAPI. Probe is detected with flurorescein. There is perhaps nothing more disturbing to a woman than a ...

GLSI-100 has received FDA fast track designation for HLA-A*02-positive and HER2-positive breast cancer, expediting its development and review process. Preliminary data from the FLAMINGO-01 trial shows ...

The highest rates of HER2 positivity were observed in bladder cancer, uterine serous carcinoma, and esophagogastric junction cancer. New research suggests the incidence of HER2 positivity is low ...

Trioar Inc. has synthesized antibody-drug conjugates comprising antibodies targeting HER2 (Neu, erbB2) covalently linked to cytotoxic drugs (particularly, MMAE and MMAF) through a linker reported to ...

Please provide your email address to receive an email when new articles are posted on . Researchers reported a 41% confirmed ORR among patients with HER2-positive disease. No patients with ...

FDA approval of PATHWAY HER2 (4B5) test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow ...

If you have HER2-positive breast cancer, your options for treatment will depend on several factors, such as the stage of cancer (early or metastatic) and the hormone receptor status of the tumor. HER2 ...